DOCSLIB.ORG

Quinapril Winthrop

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quinapril Winthrop PACKAGE LEAFLET: INFORMATION FOR THE PATIENT QUINAPRIL ZENTIVA 5 mg, 10 mg, 20 mg and 40 mg film-coated tablets Generic medicinal product Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of willness are the same as yours. - - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1.What QUINAPRIL ZENTIVA is and what it is used for 2. What you need to know before you use QUINAPRIL ZENTIVA 3. How to use QUINAPRIL ZENTIVA 4. Possible side effects 5. How to store QUINAPRIL ZENTIVA 6. Contents of the pack and other information 1. What QUINAPRIL ZENTIVA is and what it is used for QUINAPRIL ZENTIVA belongs to a group of medicines called ACE-inhibitors. It contains quinapril, which inhibits the production of certain substances present in the body that cause a rise in blood pressure . Treatment with QUINAPRIL ZENTIVA causes the blood vessels to dilate and consequently lowers blood pressure. QUINAPRIL ZENTIVA is used to treat high blood pressure and congestive heart failure. 2. What you need to know before you use QUINAPRIL ZENTIVA Do not use QUINAPRIL ZENTIVA: - If you are allergic to quinapril or other ACE-inhibitors or any of the other ingredients of QUINAPRIL ZENTIVA. - If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren. - If you suffer from hereditary or idiopathic angioneurotic oedema. - If in the past you have had episodes of angio-oedema (swelling of the legs, arms, face, mucosae or tongue) related to treatment with ACE-inhibitors. - If you are more than three months pregnant (it is also recommended to avoid using QUINAPRIL ZENTIVA during early pregnancy – see the paragraph on Pregnancy). - If you have taken or are currently taking sacubitril/valsartan, a medicine used to treat a type of long-term (chronic) heart failure in adults. Warning and precautions Please tell your doctor about any health problems you may have or have had in the past, particularly impaired renal function (including kidney transplant), dialysis, blood disorders, diabetes, liver problems, other types of heart disease (for example heart valve defects) and allergies. It is particularly important to tell your doctor if you have ever had allergic reactions that have caused swelling, for example of your face, tongue and/or throat (reactions to food and/or wasp or bee stings). Please tell your doctor if you experience excessive vomiting or diarrhoea, you are taking potent diuretics, potassium supplements, potassium-saving medications, culinary salt substitutes containing potassium or if you are on a low-sodium diet, as all of these may influence the effect of the medicinal product. Severe allergic reactions may occur when QUINAPRIL ZENTIVA is administered during treatment for hypersensitivity to bee or wasp stings (hyposensitisation) or during LDL apheresis. You should therefore tell your doctor if you are taking any of these treatments. Before any surgical procedure or anaesthesia (including for dental treatment) your doctor/dentist should be informed you are under treatment with QUINAPRIL ZENTIVA , as there is a risk of an excessive drop in blood pressure during anaesthesia. It is important to remember that patients with primary hyperaldosteronism (known also as Conn’s syndrome) – an adrenal gland disorder in which there is excessive production of the hormone aldosterone – usually do not respond to ACE-inhibitors. Talk to your doctor or pharmacist before taking Quinapril Zentiva: • if you are taking any of the following medicines, the risk of angioedema (rapid swelling under the skin in area such as the throat) is increased: - sirolimus, everolimus and other medicines belonging to the class of mTOR inhibitors (used to avoid rejection of transplanted organs); - racecadotril and other medicines belonging to the class of neprilydin (NEP) inhibitors. - concomitant use of ACE inhibitors with sacubitril/valsartan is contraindicated as this increases the risk of angioedema (See Do not use QUINAPRIL ZENTIVA and Other medicines and QUINAPRIL ZENTIVA) if you are taking any of the following medicines used to treat high blood pressure: - an angiotensin II receptor blocker (ARBs) (also known as sartans - for example valsartan, telmisartan, irbesartan), in particular if you have diabetes-related kidney problems; - aliskiren. Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals. See also information under the heading “Do not use Quinaprl Zentiva” QUINAPRIL ZENTIVA is not recommended during early pregnancy and must not be taken if you are more than three months pregnant, as it may cause severe damage to your baby if taken in this period (see the paragraph on Pregnancy). Other medicines and QUINAPRIL ZENTIVA Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This applies in particular if you are also taking: - Medicines which are most often used to avoid rejection of transplanted organs (sirolimus, everolimus, temsirolimus and other medicines belonging to the class of mTOR inhibitors). See section “Warnings and precautions”. Sacubitril/valsartan – a medicine used for treating a type of long-term (chronic) heart failure in adults (see also information under the headings “Do not take QUINAPRIL ZENTIVA and Warning and precautions”); - Medicines as racecadotril used against diarrhea (medicines belonging to the class of neprilydin (NEP) inhibitors. See section “Warnings and precautions”). - An angiotensin II receptor blocker (ARB) or aliskiren (see also information under the headings “Do not use Quinapril Zentiva” and “Warnings and precautions”). - Antibiotics belonging to the tetracycline family because QUINAPRIL ZENTIVA contains magnesium, which delays their absorption. Consequently, tetracycline should not be taken whilst taking QUINAPRIL ZENTIVA. - Medicines containing lithium because they may only be taken at the same time as QUINAPRIL ZENTIVA if the concentration of lithium in the blood is carefully monitored by your doctor. - Potassium-saving medicines, potassium supplements or salt substitutes containing potassium, diuretics (water tablets, in particular those so called potassium sparing), treatments for gout (allopurinol), medicines for controlling diabetes (oral glycaemia- lowering agents or insulin) and other drugs which can increase potassium in your body (such as heparin and co-trimoxazole also known as trimethoprim/sulfamethoxazole). QUINAPRIL ZENTIVA may reduce the excretion of potassium from the body and consequently mineral salts containing potassium or medicines that increase the level of potassium may only be taken under doctor’s orders. It is also important for your doctor to know if you are taking anti-hypertension medications, antiacids, anaesthetics, cytostatics or immunosuppressants, systemic corticosteroids, procainamide, trimethoprim, anti-inflammatory analgesics or medications for depression or mental disorders. It is important to know that consumption of alcohol, barbiturates or narcotics may cause a rise in orthostatic hypotension. QUINAPRIL ZENTIVA with food and drink QUINAPRIL ZENTIVA must not be taken with alcoholic beverages. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy ACE-inhibitor treatment must not be started during pregnancy. QUINAPRIL ZENTIVA is contraindicated during the second and third trimesters of pregnancy. You must tell your doctor if you think you may be pregnant (or if it is possible that you may become pregnant). Your doctor will probably recommend you stop taking QUINAPRIL ZENTIVA before becoming pregnant or as soon as you know you are pregnant and will recommend you take another medicine instead of QUINAPRIL ZENTIVA . QUINAPRIL ZENTIVA is not recommended at the beginning of a pregnancy and you must not take it if you are more than three months pregnant, as it may cause severe damage to your baby if taken after the third month of pregnancy. In the event of exposure to quinapril after the third month of pregnancy, an ultrasound scan of the kidneys and head are recommended. Newborns whose mothers have taken quinapril must be kept under close observation. Breast-feeding Please tell your doctor if you are breast-feeding or are about to start breast-feeding. Breast-feeding newborns (in the first few weeks after birth) and particularly premature babies is not recommended whilst taking QUINAPRIL ZENTIVA. In the case of older babies, your doctor will advise you about the risks and benefits of taking QUINAPRIL ZENTIVA whilst breast-feeding, compared to other treatments. Driving and using machines Treatment with QUINAPRIL ZENTIVA may cause dizziness or tiredness in some patients. These effects may influence your ability to drive or use machines. Please observe your personal reaction. 3. How to use QUINAPRIL ZENTIVA Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Adults Essential hypertension Monotherapy: Depending on clinical response, the dosage may be adjusted, as indicated by your doctor, up to a maintenance dose of between 20 and 40 mg/day, taken as 1 or 2 separate administrations. The usual maximum maintenance dose is 40 mg/day. Concomitant diuretic therapy: You may develop symptomatic hypotension after starting treatment with quinapril. This is much more likely to happen in patients treated with diuretics. If possible, the diuretic should be suspended 2-3 days before the start of treatment with quinapril. The starting dose is 2.5 mg of QUINAPRIL ZENTIVA in patients who have been treated with diuretics.
Load more

Recommended publications
  • Accupril® (Quinapril Hydrochloride Tablets)
    Accupril® (Quinapril Hydrochloride Tablets) WARNING: FETAL TOXICITY When pregnancy is detected, discontinue ACCUPRIL as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See Warnings: Fetal Toxicity DESCRIPTION ACCUPRIL® (quinapril hydrochloride) is the hydrochloride salt of quinapril, the ethyl ester of a non-sulfhydryl, angiotensin-converting enzyme (ACE) inhibitor, quinaprilat. Quinapril hydrochloride is chemically described as [3S-[2[R*(R*)], 3R*]]-2-[2-[[1- (ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3- isoquinolinecarboxylic acid, monohydrochloride. Its empirical formula is C25H30N2O5 •HCl and its structural formula is: Quinapril hydrochloride is a white to off-white amorphous powder that is freely soluble in aqueous solvents. ACCUPRIL tablets contain 5 mg, 10 mg, 20 mg, or 40 mg of quinapril for oral administration. Each tablet also contains candelilla wax, crospovidone, gelatin, lactose, magnesium carbonate, magnesium stearate, synthetic red iron oxide, and titanium dioxide. CLINICAL PHARMACOLOGY Mechanism of Action: Quinapril is deesterified to the principal metabolite, quinaprilat, which is an inhibitor of ACE activity in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor, angiotensin II. The effect of quinapril in hypertension and in congestive heart failure (CHF) appears to result primarily from the inhibition of circulating and tissue ACE activity, thereby reducing angiotensin II formation. Quinapril inhibits the elevation in blood pressure caused by intravenously administered angiotensin I, but has no effect on the pressor response to angiotensin II, norepinephrine or epinephrine. Angiotensin II also stimulates the secretion of aldosterone from the adrenal cortex, thereby facilitating renal sodium and fluid reabsorption.
    [Show full text]
  • Quinapril, an ACE Inhibitor, Reduces Markers of Oxidative Stress in the Metabolic Syndrome
    Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes ORIGINAL ARTICLE Quinapril, an ACE Inhibitor, Reduces Markers of Oxidative Stress in the Metabolic Syndrome 1 3 BOBBY V. KHAN, MD, PHD W. CRAIG HOOPER, PHD ing the link between inflammation, met- 1 1 SRIKANTH SOLA, MD REKHA G. MENON, MD abolic disorders, and cardiovascular 1 1 WRIGHT B. LAUTEN, BS STAMATIOS LERAKIS, MD 2 1 disease (5,6). Chronic inflammation and RAMA NATARAJAN, PHD TAREK HELMY, MD an abnormal pro-oxidant state are both found in the metabolic syndrome and may play a role in its pathogenesis (7,8). The renin-angiotensin system (RAS) plays a central role in the pathogenesis of OBJECTIVE — Patients with the metabolic syndrome often have abnormal levels of proin- atherosclerosis-related diseases. Angio- flammatory and pro-oxidative mechanisms within their vasculature. We sought to determine tensin II, the central molecule in the RAS, whether the ACE inhibitor quinapril regulates markers of oxidative stress in the metabolic syndrome. has multiple effects on inflammation, ox- idation, atherosclerotic plaque initiation, RESEARCH DESIGN AND METHODS — Forty patients with the metabolic syndrome and progression (9). In the present study, were randomized in a double-blind manner to either the ACE inhibitor quinapril (20 mg/day) or we determine potential mechanisms by matching placebo for 4 weeks. Serum markers of vascular oxidative stress were measured. which the administration of the ACE in- hibitor quinapril regulates mechanisms of RESULTS — After 4 weeks of therapy, serum 8-isoprostane was reduced by 12% in the oxidative stress in subjects with the met- Ϯ Ϯ quinapril group when compared with placebo (quinapril, 46.7 1.0; placebo, 52.7 0.9 abolic syndrome.
    [Show full text]
  • Angioedema After Long-Term Use of an Angiotensin-Converting Enzyme Inhibitor
    J Am Board Fam Pract: first published as 10.3122/jabfm.10.5.370 on 1 September 1997. Downloaded from BRIEF REPORTS Angioedema After Long-Term Use of an Angiotensin-Converting Enzyme Inhibitor Adriana]. Pavietic, MD Angioedema is an uncommon adverse effect of cyclobenzaprine, her angioedema was initially be­ angiotensin-converting enzyme (ACE) inhib­ lieved to be an allergic reaction to this drug, and itors. Its frequency ranges from 0.1 percent in pa­ it was discontinued. She was also given 125 mg of tients on captopril, lisinopril, and quinapril to 0.5 methylprednisolone intramuscularly. Her an­ percent in patients on benazepril. l Most cases are gioedema did not improve, and she returned to mild and occur within the first week of treat­ the clinic the following day. She was seen by an­ ment. 2-4 Recent reports indicate that late-onset other physician, who discontinued lisinopril, and angioedema might be more prevalent than ini­ her symptoms resolved within 24 hours. Mter her tially thought, and fatal cases have been de­ ACE inhibitor was discontinued, she experienced scribed.5-11 Many physicians are not familiar with more symptoms and an increased frequency of late-onset angioedema associated with ACE in­ palpitations, but she had no change in exercise hibitors, and a delayed diagnosis can have poten­ tolerance. A cardiologist was consulted, who pre­ tially serious consequences.5,8-II scribed the angiotensin II receptor antagonist losartan (initially at dosages of 25 mg/d and then Case Report 50 mg/d). The patient was advised to report any A 57-year-old African-American woman with symptoms or signs of angioedema immediately copyright.
    [Show full text]
  • THE DOSE an Estimation of Equivalent Doses Between Arbs and Aceis
    THE DOSE An estimation of equivalent doses between ARBs and ACEIs ARBs still currently available as of Jan 26, 2020: Twynsta (telmisartan/amlodipine): 40/5mg. 40/10mg, 80/5mg, 80mg/ 10mg Note: ~$0.73/tablet (ODB covered) Candesartan/Hydrochlorothiazide:16mg/12.5mg, 32mg/12.5mg, 32mg/25mg Irbesartan/Hydrochlorothiazide: 150/12.5mg, 300/12.5mg, 300/25mg Olmesartan/Hydrochlorothiaizde: 20/12.5mg, 40/12.5mg Valsartan/Hydrochlorothiazide: 80/12.5mg, 160/12.5mg, 160/25mg, 320/12.5mg, 320/25mg Note: Availability changes daily. Some pharmacies are able to get candesartan (4mg, 8mg, and 32mg) and irbesartan (300mg). Considerations Patients renal function and hepatic function should be taken into consideration Patients should have blood pressure, lytes and SCr checked with rotation from ARB to ACEI as clinically indicated in 1-4 weeks ACEIs can cause a dry cough in 5-35% of patients and carry a risk of angioedema (0.1-0.2%) Comparable dosages between ACEIs and ARBs- Summary of trials Lisinopril 20mg Enalapril 20mg Perindopril 4mg Ramipril 10mg Candesartan 16mg 8mg 16mg Irbesartan 150mg Telmisartan 80mg 40-80mg 40mg ~80mg Valsartan 160mg 80mg Note: There are variations for approximate equivalent dosages between ACEIs and ARBs in clinical trials. Approximate equivalent doses of ACEI for blood pressure lowering Drug Approximate Initial Daily Dose Usual Daily Maintenance Dose Maximum Daily Duration of Dose Dose Action Equivalence Between ACEIs Cilazapril 2.5mg 2.5-5mg 2.5-5mg dailya 10mg 12-24 hr Enalapril maleate 5mg 2.5-5mg 10-40mg daily (or divided bid)a 40mg 12-24 hr Fosinopril 10mg 10mg 10-40mg daily (or divided bid)a 40mg 24hr Lisinopril 10mg 2.5-10mg 10-40mg daily 80mg 24hr Perindopril 2mg 2-4mg 4-8mg daily 8mg 24hr Quinapril 10mg 5-10mg 10-20mg dailya 40mg 24hr Ramipril 2.5mg 1.25mg-2.5mg 2.5-10mg daily (or divided bid)a 20mg ~24hr a: Some patients may experience a diminished antihypertensive effect toward the end of a 24-hour dosing interval.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Patient Information Leaflet
    Package leaflet: Information for the user Accuretic® 10/12.5 mg film-coated tablets quinapril and hydrochlorothiazide Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Accuretic is and what it is used for 2. What you need to know before you take Accuretic 3. How to take Accuretic 4. Possible side effects 5. How to store Accuretic 6. Contents of the pack and other information 1. What Accuretic is and what it is used for Accuretic contains the active substances quinapril and hydrochlorothiazide. Quinapril belongs to a group of medicines called angiotensin converting enzyme (ACE) inhibitors. ACE inhibitors work by widening blood vessels in the body, which can help to reduce the pressure in the vessels. Hydrochlorothiazide belongs to a group of medicines called diuretics. Diuretics help the body to get rid of extra fluid and are used in patients with high blood pressure. Because they get rid of fluid diuretics are sometimes called ‘water tablets’. Accuretic is used to treat high blood pressure. You must talk to a doctor if you do not feel better or if you feel worse.
    [Show full text]
  • Angiotensin-Converting Enzyme (ACE) Inhibitors
    Angiotensin-Converting Enzyme (ACE) Inhibitors Summary Blood pressure reduction is similar for the ACE inhibitors class, with no clinically meaningful differences between agents. Side effects are infrequent with ACE inhibitors, and are usually mild in severity; the most commonly occurring include cough and hypotension. Captopril and lisinopril do not require hepatic conversion to active metabolites and may be preferred in patients with severe hepatic impairment. Captopril differs from other oral ACE inhibitors in its rapid onset and shorter duration of action, which requires it to be given 2-3 times per day; enalaprilat, an injectable ACE inhibitor also has a rapid onset and shorter duration of action. Pharmacology Angiotensin Converting Enzyme Inhibitors (ACE inhibitors) block the conversion of angiotensin I to angiotensin II through competitive inhibition of the angiotensin converting enzyme. Angiotensin is formed via the renin-angiotensin-aldosterone system (RAAS), an enzymatic cascade that leads to the proteolytic cleavage of angiotensin I by ACEs to angiotensin II. RAAS impacts cardiovascular, renal and adrenal functions via the regulation of systemic blood pressure and electrolyte and fluid balance. Reduction in plasma levels of angiotensin II, a potent vasoconstrictor and negative feedback mediator for renin activity, by ACE inhibitors leads to increased plasma renin activity and decreased blood pressure, vasopressin secretion, sympathetic activation and cell growth. Decreases in plasma angiotensin II levels also results in a reduction in aldosterone secretion, with a subsequent decrease in sodium and water retention.[51035][51036][50907][51037][24005] ACE is found in both the plasma and tissue, but the concentration appears to be greater in tissue (primarily vascular endothelial cells, but also present in other organs including the heart).
    [Show full text]
  • Switching Ace-Inhibitors
    Switching Ace-inhibitors http://www.ksdl.kamsc.org.au/dtp/switching_ace_inhibitors.html Change to → Enalapril Quinapril Ramipril Change from ↓ (Once daily dosing) (Once daily dosing) (Once daily dosing) Captopril Captopril 12.5mg daily Enalapril 2.5mg1 Quinapril 2.5mg Ramipril 1.25mg Captopril 25mg daily Enalapril 5mg1 Quinapril 5mg Ramipril 1.25-2.5mg Captopril 50mg daily Enalapril 7.5mg1 Quinapril 10mg Ramipril 2.5-5mg Captopril 100mg daily Enalapril 20mg1 Quinapril 20mg Ramipril 5-10mg2 Captopril 150mg daily Enalapril 40mg Quinapril 40mg Ramipril 10mg Fosinopril Fosinopril 5mg daily Enalapril 5mg Quinapril 5mg Ramipril 1.25mg Fosinopril 10mg daily Enalapril 10mg Quinapril 10mg Ramipril 2.5mg Fosinopril 20mg daily Enalapril 20mg Quinapril 20mg Ramipril 5mg Fosinopril 40mg daily Enalapril 40mg Quinapril 40mg Ramipril 10mg Lisinopril Lisinopril 5mg daily Enalapril 5mg Quinapril 5mg Ramipril 1.25mg Lisinopril 10mg daily Enalapril 10mg Quinapril 10mg Ramipril 2.5mg Lisinopril 20mg daily Enalapril 20mg Quinapril 20mg Ramipril 5mg Lisinopril 40mg Enalapril 40mg Quinapril 40mg Ramipril 10mg Perindopril Perindopril 2mg daily Enalapril 5-10mg Quinapril 5-10mg Ramipril 2.5mg Perindopril 4mg daily Enalapril 10mg-20mg Quinapril 10mg-20mg Ramipril 5mg Perindopril 8mg daily Enalapril 20-40mg Quinapril 20-40mg Ramipril 10mg Trandolapril Trandolapril 0.5mg d Enalapril 5mg Quinapril 5mg Ramipril 1.25mg Trandolapril 1mg daily Enalapril 10mg Quinapril 10mg Ramipril 2.5mg Trandolapril 2mg daily Enalapril 20mg Quinapril 20mg Ramipril 5mg Trandolapril 4mg daily Enalapril 40mg Quinapril 40mg Ramipril 10mg There are few studies comparing equivalent doses of ACE-inhibitors, for specific indications. Therefore, the above recommendations are based on clinical experiences and are not specific for any indication.
    [Show full text]
  • Oral Health Fact Sheet for Dental Professionals Adults with Congenital Cardiac Disorders
    Oral Health Fact Sheet for Dental Professionals Adults with Congenital Cardiac Disorders Congenital cardiac disorders are imperfections or malformations of the heart existing at, and usually before, birth regardless of their causation. (ICD9 code 746.9) Prevalence • Approximately 1% Manifestations Clinical varies with type of congenital defect (e.g. atrial/ventricular septal defects, pulmonary/aortic stenosis, transposition, heart valve abnormalities) • Pulmonary congestion/labored breathing • Heart murmur • Cardiomegaly • Congestive heart failure • Hypoxic spells • Cyanosis • Poor physical development • Clubbing of the terminal phalanges of the fingers Oral • Infective endocarditis risk from dental treatment • Post-operative bleeding risk in patients with anti-coagulated status following surgical procedures • May have oral manifestations caused by co-occurring disorders Other Potential Disorders/Concerns • Depression/Anxiety • Genetic and syndromic conditions (~11%) such as Down, Turner, Marfan and Ehler Danlos syndromes; osteogenesis imperfecta • Asthma • Intellectual disabilities • Esophageal atresia Management Medication The list of medications below are intended to serve only as a guide to facilitate the dental professional’s understanding of medications that can be used for Congenital Cardiac Disorders. Medical protocols can vary for individuals with Congenital Cardiac Disorders from few to multiple medications. MEDICATION TYPE MEDICATION SIDE EFFECTS/DRUG INTERACTIONS ACE inhibitors Benazepril (Lotensin) Cough, low blood pressure,
    [Show full text]
  • ACE2 As a Therapeutic Target for COVID-19; Its Role in Infectious Processes and Regulation by Modulators of the RAAS System
    Journal of Clinical Medicine Review ACE2 as a Therapeutic Target for COVID-19; Its Role in Infectious Processes and Regulation by Modulators of the RAAS System Veronique Michaud 1,2, Malavika Deodhar 1, Meghan Arwood 1, Sweilem B Al Rihani 1, Pamela Dow 1 and Jacques Turgeon 1,2,* 1 Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, FL 32827, USA; [email protected] (V.M.); [email protected] (M.D.); [email protected] (M.A.); [email protected] (S.B.A.R.); [email protected] (P.D.) 2 Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada * Correspondence: [email protected]; Tel.: +856-938-8793 Received: 11 June 2020; Accepted: 2 July 2020; Published: 3 July 2020 Abstract: Angiotensin converting enzyme 2 (ACE2) is the recognized host cell receptor responsible for mediating infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ACE2 bound to tissue facilitates infectivity of SARS-CoV-2; thus, one could argue that decreasing ACE2 tissue expression would be beneficial. However, ACE2 catalytic activity towards angiotensin I (Ang I) and II (Ang II) mitigates deleterious effects associated with activation of the renin-angiotensin-aldosterone system (RAAS) on several organs, including a pro-inflammatory status. At the tissue level, SARS-CoV-2 (a) binds to ACE2, leading to its internalization, and (b) favors ACE2 cleavage to form soluble ACE2: these actions result in decreased ACE2 tissue levels. Preserving tissue ACE2 activity while preventing ACE2 shredding is expected to circumvent unrestrained inflammatory response. Concerns have been raised around RAAS modulators and their effects on ACE2 expression or catalytic activity.
    [Show full text]
  • Angiotensin Modulators: ACE Inhibitors and Direct Renin Inhibitors Review 10/09/2008
    Angiotensin Modulators: ACE Inhibitors and Direct Renin Inhibitors Review 10/09/2008 Copyright © 2004 - 2008 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 5181 Natorp Blvd., Suite 205 Mason, Ohio 45040 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Comments and suggestions may be sent to [email protected].
    [Show full text]
  • QUINAPRIL Quinapril 5 Mg, 10 Mg, 20 Mg Tablets
    CONSUMER MEDICINE INFORMATION ARROW - QUINAPRIL Quinapril 5 mg, 10 mg, 20 mg Tablets What is in this leaflet This leaflet answers some common questions about ARROW - QUINAPRIL. It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have benefits and risks. Your doctor has weighed the risks of you taking ARROW - QUINAPRIL against the benefits they expect it will have for you. If you have any concerns about taking this medicine, talk to your doctor or pharmacist. Keep this leaflet with your medicine. You may need to read it again. What ARROW - QUINAPRIL is used for ARROW - QUINAPRIL is used to lower high blood pressure (hypertension). It is also used to treat heart failure. Hypertension ARROW – QUINAPRIL is used to lower high blood pressure (hypertension). Everyone has blood pressure. This pressure helps get your blood all around your body. Your blood pressure may be different at different times of the day, depending on how busy or worried you are. You have hypertension (high blood pressure) when your blood pressure stays higher than is needed even when you are calm and relaxed. There are usually no symptoms of hypertension. The only way of knowing that you have hypertension is to have your blood pressure checked on a regular basis. If high blood pressure is not treated it can lead to serious health problems, including stroke, heart disease and kidney failure. Heart Failure Heart failure means that the heart muscle cannot pump blood strongly enough to supply all the blood needed throughout the body.
    [Show full text]